MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2016 International Congress

June 19-23, 2016. Berlin, Germany.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z
  • E-counselling to movement disorder callers in Africa

    M. Busgopaul (Nouvelle France, Mauritius)

  • E326K GBA polymorphism and Parkinson’s disease in Russian population

    K.A. Senkevich, M.A. Nikolaev, A.E. Kopytova, T.S. Usenko, I.V. Miliukhina, A.A. Timofeeva, A.F. Yakimovskii, S.N. Pchelina (Saint Petersburg, Russia)

  • Early clinical features of paraneoplastic cerebellar degeneration: Diagnostic outcomes of adult onset cerebellar ataxia

    J. Zhang, Z. Xu, J.Y.H. Chai, L. Tan (Beijing, People's Republic of China)

  • Early grey matter changes in structural covariance networks in Huntington’s disease

    E.M. Coppen, J. van der Grond, A. Hafkemeijer, S.A.R.B. Rombouts, R.A.C. Roos (Leiden, Netherlands)

  • Early retirement and loss of income among X linked dystonia parkinsonism (XDP / DYT3) patients in Capiz, Roxas City Philippines

    P.J.B. Acuna, C.L. Go (Boston, MA, USA)

  • Early stridor onset predicts survival in multiple system atrophy

    G. Giannini, G. Calandra-Buonaura, F. Mastrolilli, M. Righini, M.L. Bacchi-Reggiani, P. Guaraldi, F. Provini, P. Cortelli (Bologna, Italy)

  • EARLYSTIM: STN-DBS alleviates behavioural side effects of dopamine replacement therapy when compared to best medical treatment

    E. Lhommée, W. Lars, C. Virginie, K. Witt, F. Maier, L. Tonder, L. Timmermann, T. Hälbig, F. Pineau, F. Durif, T. Witjas, J.L. Houeto, P. Krack (Grenoble, France)

  • EBM review on the diagnostic work-up of multiple system atrophy

    I. Stankovic, A. Antonini, A. Berardelli, C. Colosimo, A. Fanciulli, S. Fox, B. Frauscher, H. Kaufmann, V.S. Kostic, F. Krismer, P. Low, W. Meissner, M.T. Pellecchia, W. Poewe, K. Seppi, S. Tsui, H. Watanabe, G.K. Wenning, On behalf of the MODIMSA EBM Working Group (Belgrade, Serbia)

  • ECG-based cardiopulmonary coupling for sleep stability assessment in patients with amyotrophic lateral sclerosis

    S. Mariani, P. Congiu, G. Milioli, G. Gioi, G. Borghero, F. Marrosu, R.J. Thomas, A.L. Goldberger, M. Puligheddu (Boston, MA, USA)

  • EEG Spectral power changes prior to non-epileptic seizures: A pilot study

    A.M. Meppelink, I. Parees, M. Beudel, S. Little, M. Edwards (Groningen, Netherlands)

  • Effect of bilateral subthalamic nuclei deep brain stimulation on impulse control disorders in PD

    R. Borgohain, P.K. Pesala, R.K. Mridula, A.K. Puligopu, V.V.P. Kagita, S.A. Jabeen, M.A. Kanikannan (Hyderabad, India)

  • Effect of botulinum toxin on the non-motor symptoms of dystonia

    E. Shakweh, R. Pearce, N. Pavese (London, United Kingdom)

  • Effect of dopamine and L-3,4 – dihydroxyphenylalanine in treatment of experimental parkinsonism

    M.U. Kulmanova (Tashkent, Uzbekistan)

  • Effect of European physiotherapy guideline for Parkinson´s disease and Microsoft Kinect® adventures games training on postural control, cognition and quality of life: Randomized clinical trial

    J.E. Pompeu, K.G. Silva, T.B. Freitas, R.A. Nuvolini, F. Doná, C. Torriani-Pasin, F.F. Ganaça, H.B. Ferraz (Sao Paulo, Brazil)

  • Effect of frequency modulation on freezing of gait in PD patients after bilateral STN DBS

    R.M. Kandadai, V.V.P. Kagita, S.A. Jabeen, A.K. Puligopu, M.A. Kanikannan, R. Borgohain (Hyderabad, India)

  • Effect of genetic variation in SNCA and APOE on cerebrospinal fluid protein levels in patients with Parkinson’s disease and controls

    G. Machetanz, K. Lohmann, C.M. Lill, C. Klein, C. Trenkwalder, B. Mollenhauer (Kassel, Germany)

  • Effect of intra-striatal 6-OHDA lesion on extra-striatal structures in the mouse

    B. Becker, M. Demirbas, C. Beyer, S. Tan, M. Kipp (Aachen, Germany)

  • Effect of L-DOPA on re-emergent tremor in Parkinson’s disease: A neurophysiological assessment

    M. Wilken, A. Medina, M.D. Rossi, A.D. Rivero, M. Merello, M. Hallett (Buenos Aires, Argentina)

  • Effect of marijuana on Essential Tremor: A case report

    D.P. Sutherland (Sarasota, FL, USA)

  • Effect of nelotanserin on objective sleep parameters in a phase 2 study in patients with insomnia

    W. Wen, L. Friedhoff, K. Kishnani, S. Ramaswamy, M. Sanchez, W. Shanahan (New York, NY, USA)

  • Effect of outside influences on the therapeutic benefits of botulinum toxin injections

    D.C. Taylor, P.A. LeWItt, P. Kaminski (Royal Oak, MI, USA)

  • Effect of over(exaggerated) articulation technique in voice and speech of individuals with Parkinson’s disease with deep brain stimulation

    G.L.A. Diaféria, F.A.M. Bento, M. Padovani, E.T. Fonoff, M.S. Behlau (São Paulo, Brazil)

  • Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

    P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

  • Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study

    C. Stuijt, T.V. Laar (Groningen, Netherlands)

  • Effect of repeated intravenous amantadine infusions in patients with Parkinson’s disease

    A. Khlebtovsky, I. Steiner, R. Djaldetti, T. Treves (Petach Tikva, Israel)

  • Effect of right DLPFC-repetitive transcranial magnetic stimulation (rTMS) on tardive dyskinesia in patients with psychosis

    S. Lavania, A. Pattojoshi, A.H. Khan, S. Lavania (Agra, India)

  • Effect of rivastigmine in Parkinson’s disease dementia – A logitudinal observational study

    S. Raha, L. Ebenezer (Bridgend, United Kingdom)

  • Effect of STN-DBS on impulse control disorder and affective behavioral complications of Parkinson’s disease: A 1-year longitudinal study

    S.M. Omarova, N.V. Fedorova, E.V. Bril, A.A. Tomskiy, A.A. Gamaleya (Moscow, Russia)

  • Effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson’s disease: 7- year follow-up

    G. Ehm, H.J. Kim, B.S. Jeon, D.G. Kim, S.H. Paek (Goyang, Korea)

  • Effect of vibration on motor performance: A new intervention to improve bradykinesia in Parkinson’s disease?

    A. Macerollo, C. Palmer, T. Foltynie, P. Korlipara, P. Limousin, M. Edwards, J. Kilner (London, United Kingdom)

  • Effect of zonisamide on post-traumatic Holmes’ tremor

    T. Jo, S. Sekimoto, G. Oyama, N. Izawa, S. Ueno, Y. Shimo, A. Nakajima, M. Nakajima, A. Umemura, H. Arai, N. Hattori (Tokyo, Japan)

  • Effectiveness and micro-electrodes findings of deep brain stimulation of the STN via a parietal approach in post-infectious previously implanted Parkinson´s patients

    W.O. Contreras Lopez, L. Batista, A. Azevedo, M.J. Teixeira, E.T. Fonoff (São Paulo, Brazil)

  • Effectiveness of a multidisciplinary PD clinic in improving quality of life

    H.F. Chan, D.K.W. Chau, T. Fung, I. Chan, Y.F. Cheung, W.C. Fong (Hong Kong, Hong Kong)

  • Effectiveness of bilateral pallidal deep brain stimulation in a patient with dystonia associated to neurodegenerative ataxia: Follow-up to 18 months

    P.A. Millan, J.M. Cardenas (Cali, Colombia)

  • Effectiveness of duodenal levodopa/carbidopa infusion gel (LCIG) therapy on the neuropsychiatric disturbances of advanced Parkinson’s disease (EDIS study)

    M.J. Catalan, P. Montero, J. Herreros, J.M. Arbelo, P. Martinez-Martin (Madrid, Spain)

  • Effectiveness of Lee Silverman voice treatment big on improving gait and quality of life in Parkinson’s disease patients after STN-DBS

    V.V.P. Kagita, N.N. Mohd, A.K. Puligopu, R.M. Kandadai, M.A. Kanikannan, S. Jabeen, R. Borgohain (Hyderabad, India)

  • Effectiveness of Levodopa responsiveness of Blink reflex recovery: An objective method to differentiate Parkinsonian syndromes

    C. Gaddipati, M. Umaiorubahan, C.U. Velmurugendran, V. Shankar (Chennai, India)

  • Effectiveness of occupational therapy multi-domain group therapy program for Parkinson’s disease

    R.K.M. Wong, D.S.W. Tsang, C.K.Y. Lau, A.Y.Y. Chan, D.T.M. Chan, X. Zhu, W. Poon, V.C.T. Mok (Hong Kong, Hong Kong)

  • Effectivity and safety of rotigotine transdermal patch on motor and cognitive dysfunctions in Parkinson’s disease with dementia and dementia with Lewy bodies

    K. Ohta, Y. Kujuro, T. Osada, T. Toguchi, Y. Shinohara (Tokyo, Japan)

  • Effects of a 12-week exercise program on cognition in Parkinson’s disease

    J.C. Johnson, A.L. Svitak, M.T. Farrell, S.C. Mosch, F. Yu, E.D. Parker, L.R. Hanson (Saint Paul, MN, USA)

  • Effects of age and gender on brainstem MR-planimetry

    S. Mangesius, A. Hussl, E. Reiter, B. Pinter, F. Krismer, C. Scherfler, C. Müller, A. Djamshidian, M. Schocke, W. Poewe, K. Seppi (Innsbruck, Austria)

  • Effects of antidepressants on gait parameters in Parkinson’s disease

    D. Martinez-Ramirez, J.C. Giugni, W. Deeb, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

  • Effects of Arachidonyl-2′-chloroethylamide (ACEA), a selective CB1 receptor agonist, in MPTP mouse model of Parkinson’s disease

    M. Omidbeigi, S. Asaadi, A. Zali (Tehran, Islamic Republic of Iran)

  • Effects of cerebellar theta-burst stimulation on arm and neck movement kinematics in patients with focal dystonia

    M. Bologna, G. Paparella, A. Fabbrini, G. Leodori, L. Rocchi, M. Hallett, A. Berardelli (Pozzilli, Italy)

  • Effects of combined repetitive transcranial magnetic stimulation and treadmill training on gait performance in Parkinson’s disease

    C.L. Chung, M.K.Y. Mak (Hong Kong, Hong Kong)

  • Effects of deep brain stimulation in the nucleus entopeduncularis on neuronal network activity after apomorphine-induced deficient sensorimotor gating in a rat model

    K. Schwabe, L. Götz, J.K. Krauss, M. Alam (Hannover, Germany)

  • Effects of dual task on upper extremity function and postural control in patients with Parkinson’s disease

    S.M.A.A. Pompeu, B.R.B. Moraes, J.E. Pompeu (São Paulo, Brazil)

  • Effects of exercise intervention on balance and gait performance, and balance confidence in people with Parkinson’s disease – A meta-analysis

    M.K. Mak, I.S. Wong-Yu (Hong Kong, People's Republic of China)

  • Effects of gender, age and hyposmia on cognitive functions in healthy elderly individuals at risk for Parkinson’s disease: Results from the TREND study

    S. Heinzel, U. Suenkel, F.G. Metzger, E. Schaeffer, B. Roeben, R. Yilmaz, S. Lerche, K. Brockmann, A.K. von Thaler, I. Liepelt-Scarfone, G.W. Eschweiler, A.J. Fallgatter, W. Maetzler, D. Berg (Tübingen, Germany)

  • Effects of levodopa on adaptation of reactive stepping in people with Parkinson’s disease

    F.B. Horak, B. Dijstra, J.G. Nutt, D.S. Paterson (Portland, OR, USA)

  • Effects of movement rate and amplitude on repetitive finger motion in people with Parkinson’s disease and freezing of gait

    M.P. Pereira, S. Vercruysse, E. Heremans, A. Nieuwboer (Leuven, Belgium)

  • Effects of nilotinib on safety in open-label phase I clinical trial in Parkinson’s disease with dementia and Lewy body dementia

    F. Pagan, E. Valadez, Y. Torres-Yaghi, R. Falconer, R. Mills, S. Rogers, B. Wilmarth, M. Hebron, C. Moussa (Washington, DC, USA)

  • Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial

    L. Bartolomei, M. Malaguti, A. Pastore, G.M. Minicuci, N. Bonetto, S. Ferrari, M. Pellegrini (Vicenza, Italy)

  • Effects of pyridostigmine bromide vs. fludrocortison in the treatment of orthostatic hypotension in Parkinson’s disease

    S.R. Schreglmann, F. Büchele, M. Sommerauer, L. Epprecht, G. Kägi, S. Hägele-Link, O. Götze, L. Zimmerli, D. Waldvogel, C.R. Baumann (London, United Kingdom)

  • Effects of safinamide in patients with Parkinson’s disease measured by Parkinson’s KinetiGraphTM

    I. Suttrup, V. Zentsch, J. Schroeder, T. Warnecke (Muenster, Germany)

  • Effects of subthalamic deep brain stimulation in motor and nonmotor function in Parkinson’s disease patients with parkin mutation

    L.M. Oliveira, R.G. Cury, H.F. Chien, J.G. Santos, M.G. Ghilardi, R.B. Machado, E.T. Fonoff, B.R. Egberto (São Paulo, Brazil)

  • Effects of the biodex stability system training on balance, gait and fatigue in Parkinson’s disease

    G. Singh, R. Pahwa, K.E. Lyons, Y. Colgrove, N.K. Sharma (Troy, NY, USA)

  • Effects of videogame step training on gait adaptability in people with Parkinson´s disease – A randomized controlled trial

    M.J.D. Caetano, J.C. Menant, C.G. Canning, J. Song, D. Schoene, M. Brodie, S.R. Lord (Sydney, Australia)

  • Effects of zonisamide on dementia with Lewy bodies (DLB): A post-hoc analysis of phase 2 study for parkinsonism in DLB patients

    M. Murata, M. Nakamura, H. Maruyama (Tokyo, Japan)

  • Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial

    K. Hannink, L. ter Brake, A. Wertenbroek, K. Movig, J. van der Palen, L. Dorresteijn (Enschede, Netherlands)

  • Efficacy and safety of a L-dopa delivery and monitoring medical device

    Y.G. Tirat-Gefen (Fairfax, VA, USA)

  • Efficacy and safety of abobotulinumtoxinA in craniocervical dystonia and hemifacial spasm

    A. Jesic, D. Stefanovic, N. Delibasic, J. Radanov, M. Cvijanovic (Victoria, Seychelles)

  • Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study

    R. Miguel, M. Mendonça, R. Barbosa, F. Ladeira, T. Lampreia, J. Vale, P. Bugalho (Lisbon, Portugal)

  • Efficacy of 4845 botulinum toxin (BoNT) treatment cycles, and clinical strategies after a failed cycle

    P. Tanvijit, A.P. Moore (Bangkok, Thailand)

  • Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

    S.H. Isaacson (Boca Raton, FL, USA)

  • Efficacy of deep brain stimulation (DBS) patient education and post operative support: A summary of 3 months monitoring of unscheduled patient phone requests. An Australian private neurology clinic experience

    K.A. O'Maley, P. Poortvliet, L.J. Cooke, P.A. Silburn (Brisbane, Australia)

  • Efficacy of long-term treatment with istradefylline and analysis of the expression of A2A receptor protein and post-transcriptional DNA methylation

    N. Kanzato, K. Nakachi, T. Naka, M. Higa, S. Mochizuki, Y. Miyamae (Okinawa Prefecture, Haebaru-cho, Japan)

  • Efficacy of the bilateral subthalamic stimulation in Parkinson’s disease, results from the Neuromodulation Centre in Budapest

    A. Kelemen, L. Eröss, D. Albert, I. Rózsa, E. Csibri, L. Entz, D. Fabó, L. Halász, G. Rudas, P. Barsi, P. Golopencza, G. Tamás (Budapest, Hungary)

  • Efficiency of carotid endarterectomy in vascular parkinsonism in patients with stenotic carotid artery disease

    M. Ataniyazov, G. Rakhimbaeva, K. Ataniyazova (Tashkent, Uzbekistan)

  • Efficiency of intraoperative microelectrode recording in patients with deep brain stimulation of the subthalamic nucleus. Three-year comparative research

    N. Gubareva, E. Bril, A. Tomskiy, N. Fedorova, S. Asriyants (Moscow, Russia)

  • Eight weeks of home-based balance training not as effective as therapist-based during dual tasks

    E.M. Atterbury, K.E. Welman (Stellenbosch, South Africa)

  • Electric stimulation of the nucleus subthalamicus is able to modulate prepulse inhibition. A pilot study in Parkinson´s disease

    J. Schuster, I. Galazky, M. Kühne, S. Specht, S. Nullmeier, H.J. Heinze, A. Kupsch, T. Zaehle, J. Voges, P. Panther (Magdeburg, Germany)

  • Electromyographic and kinematic patterns in runner’s dystonia

    O.F. Ahmad, P. Ghosh, C. Lungu, B. Karp, C. Stanley, K. Alter (Bethesda, MD, USA)

  • Electrophysiological activity of anatomically identified STN subterritories in Parkinson’s disease

    N.G. Pozzi, G. Arnulfo, F. Steigerwald, A. Canessa, R. Nickl, C. Matthies, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)

  • Elemental profiles as biomarkers for diagnosis and disease progression of Parkinson’s disease

    F. Maass, M. Börger, A. Fischbach, B. Michalke, M. Bähr, I. Zerr, P. Lingor (Göttingen, Germany)

  • Elevated SNCA expression in CD45+ peripheral blood cells in patients with dementia with Lewy bodies

    N. Nikolaev, B. Lu.A., P.A. Andoskin, A. Emelyanov, A.E. Kopytova, K.A. Senkevich, I.V. Milyukhina, S.N. Pchelina (Saint-Petersburg, Russia)

  • Elucidating mechanisms of endogenous disease protection resulting in reduced penetrance in PINK1 deficiency

    M. Vos, C. Böhm, C. Klein (Lübeck, Germany)

  • Emotion processing in Parkinson’s disease – Possible link between inability to decode complex emotional stimuli and impairment of executive functions

    E. Klimiec, K. Kowalska, P. Pasinska, A. Szyper, T. Dziedzic, A. Slowik, A. Klimkowicz-Mrowiec (Krakow, Poland)

  • Emotional facial EMG responses are affected in Huntington’s disease

    C.C. Kordsachia, I. Labuschagne, J. Stout (St. Kilda, Australia)

  • Emotional modulation of the startle reflex in essential tremor: Evidence of altered cerebellar input into limbic circuitry?

    J.A. Lafo, A.E. Mikos, B.M. Scott, M.S. Okun, D. Bowers (Gainesville, FL, USA)

  • Emotional valence and arousal ratings from rewarding and fearful stimuli are not influenced by levodopa in Parkinson’s disease

    T. Serranova, T. Sieger, P. Dušek, E. Ruzicka, R. Jech (Prague, Czech Republic)

  • Employing intraoperative microelectrode recordings during "asleep" deep brain stimulation surgery of the globus pallidus internus in Parkinson’s disease

    J.E. Quintero, N.S. Timoney, J.H. Smith, F. McCarron, G.A. Gerhardt, C.G. van Horne (Lexington, KY, USA)

  • Empowering Parkinson’s patients to declare pain: A multicenter report of the use of the first Parkinson’s pain questionaire (King’s PD pain quest)

    A.M. Rizos, P. Martinez-Martin, S. Pal, R. Sophia, C. Carroll, D. Martino, C. Falup-Pecurariu, B. Kessel, T. Andrews, D. Paviour, A. Sauerbier, A. Martin, M. Parry, L. Perkins, D. Trivedi, T. Chiwera, P. Odin, A. Antonini, K. Ray Chaudhuri, On behalf of EUROPAR, The IPMDS Non-Motor PD Study Group (London, United Kingdom)

  • Endoscopic-guided injection of botulinum toxin into the longus capitis muscle and into the obliquus superior part of the longus colli muscle in dystonic antecaput

    G. Reichel, A. Stenner, H. von Sanden, L. Herrmann, C. Feja, S. Löffler (Zwickau, Germany)

  • Endoscopically-documented pharyngeal dystonia due to neuroleptic use without response to alcohol

    J.P. Squires, W.L. Severt, M.J. Pitman (New York, NY, USA)

  • Engrailed enhances dopamine synthesis in healthy dopaminergic neurons

    D. Alvarez-Fischer, M. Baaske, F. Vulinovic, J. Fuchs, P. Seibler, A. Rakovic, A. Prochiantz, C. Klein (Lübeck, Germany)

  • Enroll-HD: A global clinical research platform for Huntington’s disease

    T.A. Mestre, C. Fitzer-Attas, J. Giuliano, B. Landwehrmeyer, C. Sampaio (Ottawa, Canada)

  • Enteric neurons reveal substantial in vivo mitochondrial changes in Parkinson’s disease

    P.M.A. Antony, A.S. Baumuratov, M. Ostaszewski, F. He, L. Salamanca, L. Antunes, J. Weber, L. Longhino, P. Derkinderen, R. Balling, W. Koopman, N. Diederich (Belvaux, Luxembourg)

  • Epidemiological and clinical profile of essential blepharospasm and its response to treatment with TBA over a 11-year period

    J.R.R. Manoel, U.C. Júnior, D.P. Nones, F.M.B. Germiniani, H.A.G. Teive (Curitiba, Brazil)

  • Epidemiological investigation of yips among Golfers in Japan

    Y. Gon, M. Mihara, S. Kawamura, K. Nakata, D. Kabata, A. Shintani, H. Mochizuki (Suita, Japan)

  • Epidemiology and economic burden of falls and fractures in patients with Huntington’s disease

    D.O. Claassen, P. Donga, S. Rajagopalan, L.M. De Boer, B. Carroll, S. Gandhi (Nashville, TN, USA)

  • Epigenome-wide association study of Parkinson’s disease

    B. Ritz, Y.H. Chuang, S. Horvath, Y. Bordelon, J. Bronstein (Los Angeles, CA, USA)

  • ESCRT-0 dysfunction compromises autophagic degradation of protein aggregates and facilitates ER stress-mediated neurodegeneration via apoptotic and necroptotic pathways

    T. Hasegawa, R. Oshima, K. Tamai, N. Sugeno, A. Kikuchi, J. Kobayashi, S. Yoshida, A. Takeda, N. Tanaka, M. Aoki (Sendai, Japan)

  • Esophageal involvement in multiple system atrophy

    T. Shimohata, H. Taniguchi, H. Nakayama, K. Hori, M. Inoue, M. Nishizawa (Niigata, Japan)

  • Essential tremor: Characterization according to their phenotypes and their association with Parkinsonian signs

    J.S. Bestoso, L. Ciancaglini, C.V. Stefani, L.A. di Napoli, J.I. Rojas, D.J. Bauso, E. Cristiano (Caba, Argentina)

  • Establishment of InMotion, an independent, fee-free community center for persons with movement disorders

    D.E. Riley, K.M. Jaffe, J.Z. Peters (Warrensville Heights, OH, USA)

  • Ethnic differences in rates of Parkinson’s in New Zealand: A nation-wide prevalence and incidence study

    T.L. Pitcher, D.J. Myall, M.R. MacAskill, J.F. Pearson, C.J. Lacey, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

  • European pediatric normative values for the scale for assessment and rating of ataxia (SARA)

    T.F. Lawerman, R. Brandsma, R.J. Lunsing, J.G.M. Burgerhof, D.A. Sival, On behalf of the Childhood Ataxia and Cerebellar Study Group of the European Pediatric Neurology Society, N. Barisic, P. Baxter, E. Bertini, L. Blumkin, V. Brankovic, G.E. Calabro, C.E. Catsman-Berrevoets, D. Craiu, B. Dan, A. Dica, T. Franciskovic, J. Gburek-Augustat, S. Grunt, H. Hartley, F. Kammoun, C. Kennedy, M.J. Kuiper, I. Lehman, A. Lustenberger, F. Mancini, M. Mirabelli-Badenier, E. Mulder-den Hartog, M. Steinlin, M. Synofzik, C.C. Triki, E.M. Valente, G. Vasco, A. Zekavica (Groningen, Netherlands)

  • European physiotherapy guideline for Parkinson’s disease: Information for neurologists

    D.L.M. Radder, M.J. Faber, N.M. de Vries, B.R. Bloem, S.H.J. Keus (Nijmegen, Netherlands)

  • Evaluating bradykinesia: How many finger taps are needed?

    E. Ruzicka, R. Krupicka, K. Zarubova, J. Rusz, R. Jech, D. Stanek, Z. Szabo (Praha, Czech Republic)

  • Evaluating Parkinsonian motor features via the routine use of consumer electronics – neuroQWERTY

    Á. Sánchez-Ferro, C.S. Mendoza, I. Butterworth, M. Matarazzo, P. Montero, R. Trincado, T. Arroyo Gallego, V. Puertas Martín, M.J. Catalán, J.A. Molina, F. Bermejo-Pareja, L. Giancardo (Móstoles, Spain)

  • Evaluating quantitative EEG (QEEG) measures to differentiate between Parkinson’s disease (PD) patients and healthy individuals

    M. Chaturvedi, F. Hatz, U. Gschwandtner, V. Roth, P. Fuhr (Basel, Switzerland)

  • Evaluating swallowing function in patients with Huntington disease enrolled in the first-HD study

    S.A. Frank, D.O. Claassen, S. Janicki, D. Oakes, D. Stamler, V. Sung, C. Vaughn, C.M. Testa, On behalf of First-HD HSG Investigators (Boston, MA, USA)

  • Evaluating the effects of deep brain stimulation (DBS) in mice with spinocerebellar ataxia (SCA1)

    V. Vedam-Mai, K. McFarland, Q. Zhang, H. Kim, R. Nathu, S. Kurtovic, K. Savery, T. Ashizawa, M.S. Okun (Gainesville, FL, USA)

  • Evaluating the natural history of prodromal PD in the PARS cohort

    D. Jennings, A. Siderowf, M. Stern, K. Marek, PARS Study Investigators (New Haven, CT, USA)

  • Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension

    S.H. Isaacson, S. Brillman, N. Chhabria (Boca Raton, FL, USA)

  • Evaluation of impulse control disorders in fluctuating Parkinson’s disease patients under opicapone treatment

    N. Lopes, J. Ferreira, A. Lees, T. Müller, H. Reichmann, H. Gama, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

  • Evaluation of kinematic parameters of potential clinical use extracted from Microsoft Kinect V2 motor assessments

    K. Otte, B. Kayser, S. Mansow-Model, A.U. Brandt, J. Verrel, T. Schmitz-Hübsch (Berlin, Germany)

  • Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6

    T. Xie, D. Appelbaum, J. Bernard, M. Padmanaban, Y. Pu, C. Gomez (Chicago, IL, USA)

  • Evaluation of quality of life (QOL), patient- and clinician-reported outcomes with deutetrabenazine treatment of chorea in Huntington disease in first-HD

    C.M. Testa, D.O. Claassen, D. Oakes, D. Stamler, V. Sung, S. Frank, On behalf of the First-HD HSG Investigators (Richmond, VA, USA)

  • Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials

    J.P. Seibyl, D. Jennings, K. Marek (New Haven, CT, USA)

  • Evaluation of respiratory and depression levels of patients with Parkinson’s disease

    E.E. Okuyucu, O. Canbay, E. Dogru, I. Huzmeli, N. Katayifci, F. Duman, N.C. Korkmaz, B. Yucekaya, E. Seker (Hatay, Turkey)

  • Evaluation of stigmatization and quality of life before and after botulinum toxin treatment in hemifacial spasm

    B. Yuksel, F. Genc, A. Yaman, P. Dogan Ak, E. Ozaydin Goksu, A. Aybar, Y. Bicer Gomceli (Antalya, Turkey)

  • Evaluation of the [ 99mTc] – TRODAT- 1 SPECT in the diagnosis of Parkinson’s disease and other movement disorders

    G. Fabiani, R. Martins Filho, H.A.G. Teive (Campina Grande do Sul, Brazil)

  • Evaluation of the accuracy of stereotactic DBS electrode implantation by post-operative image fusion

    P. Fricke, S. Johannes, R. Nickl, R.I. Ernestus, F. Steigerwald, J. Volkmann, C. Matthies (Würzburg, Germany)

  • Evaluation of the role of oxidative stress in Parkinson’s disease and Parkinson plus syndrome

    R. Qadri, M.A. Faiq, M. Behari, V. Goyal, A.K. Mukhopadhyay (New Delhi, India)

  • Evaluation of the surface based measures to discriminate progressive supranuclear palsy from corticobasal syndrome

    N. Upadhyay, A. Suppa, M.C. Piattella, F.D. Stasio, C. Colonnese, C. Colosimo, A. Berardelli, P. Pantano (Rome, Italy)

  • Evidence of striatal dopaminergic dysfunction Sydenham’s chorea in remission with (99m)Tc-TRODAT-1 SPECT

    R. Maciel, D. Maia, C.F. de Lima, F. Cardoso (Belo Horizonte, Brazil)

  • Evolution of mild Parkinsonian signs in a longitudinal population-based cohort

    J. Hampf, S. Tunc, J. Graf, K. Hückelheim, E.J. Vollstedt, B. Staemmler, C. Klein, M. Kasten (Luebeck, Germany)

  • Examining the clinical profile of nelotanserin, a novel agent in development for Lewy body dementia

    W. Wen, K. Kishnani, S. Ramaswamy, S. Piscitelli (New York, NY, USA)

  • Excessive daytime sleepiness is mediated by loss of caudate dopaminergic function in Parkinson’s disease

    T. Yousaf, G. Pagano, F. Niccolini, M. Politis (London, United Kingdom)

  • Executive function and verbal fluency in patients with Parkinson’s disease

    A.F. Barbosa, M.C. Voos, C.O. Souza, J. Chen, H.F. Chien, D.V. Francato, E.R. Barbosa, L.L. Mansur (São Paulo, Brazil)

  • Exercise induced analgesia is present in people with Parkinson’s disease

    N.E. Allen, N. Moloney, L.M. Hassett, C.G. Canning, S.J.G. Lewis, K. Cruz-Mavignier, B.K. Barry (Lidcombe, Australia)

  • Exercise-induced adaptive neuroplasticity in the MPTP mouse model of Parkinson’s disease

    C.J.H.M. Klemann, G. Poelmans, G.J.M. Martens, J.E. Visser (Nijmegen, Netherlands)

  • Exome sequencing in dementia with Lewy bodies

    S.W. Scholz, J.T. Geiger, J. Ding, B. Crane, O. Pletnikova, C. Letson, T.M. Dawson, L.S. Rosenthal, A. Pantelyat, J.R. Gibbs, M. Albert, D.G. Hernandez, A.E. Hillis, A.B. Singleton, D.J. Stone, J.A. Hardy, J.C. Troncoso (Bethesda, MD, USA)

  • Exome sequencing in the Czech patients with early-onset Parkinson’s disease

    D. Kemlink, B. Schormair, O. Fiala, D. Zahorakova, P. Martasek, J. Roth, J. Winkelmann, E. Ruzicka (Praha 2, Czech Republic)

  • Exome sequencing reveals homozygous mutations in SACS, ATCAY, and MCOLN1 in three Pakistani families with complex dystonia

    H. Manzoor, N. Brüggemann, F. Hinrichs, H.M.J. Hussain, M. Wajid, T. Bäumer, A. Münchau, S. Naz, K. Lohmann (Lahore, Pakistan)

  • Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report

    C. Han, J. Huang, K. Ma, Y. Shen, L. Liu, G. Zhang, X. Xu, J. Li, H. Jiang, S. Guo, Y. Xia, L. Wang, N. Xiong, T. Wang (Wuhan, People's Republic of China)

  • Expanding the spectrum of ATP1A3 related disorders: Continuum from alternating hemiplegia of childhood to rapid-onset dystonia parkinsonism?

    S.A. Rodríguez-Quiroga, D. González-Moron, S.A. Vishnopolska, G.L. Vigo, M. Cordoba, N. Medina, T. Arakaki, N.S. Garretto, M.A. Kauffman (Caba, Argentina)

  • Expanding the spectrum of PEX10-related peroxisomal biogenesis disorders: Slowly progressive recessive ataxia

    M. Renaud, C. Guissart, S. Ferdinandusse, D. Cheillan, O. Lagha-Boukbiza, M. Mallaret, J. Muller, C. Tranchant, M. Anheim, M. Koenig (Strasbourg cedex, France)

  • Experience of pallidal deep brain stimulation (DBS) in dystonia at a tertiary care centre in India

    D. Srinivas, R. Yadav, K. Jhunjhunwala, P. Pal (Bangalore, India)

  • Experience with utilization of rytary in the clinical setting

    Y. Kianirad, T. Simuni, C. Zadikoff, D. Bega, M. Afshari, S. Jonnalagadda (Chicago, IL, USA)

  • Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

    S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

  • Exploratory efficacy of opicapone in fluctuating Parkinson’s disease patients at different stages of symptom progression

    N. Lopes, J. Ferreira, A. Lees, W. Poewe, H. Reichmann, A. Santos, C. Oliveira, J.F. Rocha, P. Soares-da-Silva (Porto, Portugal)

  • Exploring aging-VMAT2 gene-rotenone interactions in a cell model for Parkinson’s disease

    H. Jiang, J. Li, C. Han, K. Ma, L. Liu, Y. Shen, L. Wang, S. Guo, Y. Xia, J. Huang, T. Wang (Wuhan, People's Republic of China)

  • Exploring association of GBA variants with pre-diagnostic features of PD in the PREDICT-PD cohort: A nested case-control study

    L. R'Bibo, N.E. Mencacci, A. Schrag, J.P. Bestwick, L. Peress, J. Masters, G. Giovannoni, A.J. Lees, J. Hardy, N.W. Wood, A.J. Noyce (London, United Kingdom)

  • Exploring hospitalizations and visits to the emergency room of patients with Parkinson’s disease: A ten years’ follow-up

    M.T. Montojo, Y. Macias, M. ÁLvarez, C. Martín, L. Borrega, L. Vela (Alcorcón, Spain)

  • Exploring structural covariance networks of gray matter in Parkinson’s disease

    L.J. de Schipper, J. van der Grond, J. Marinus, J.J. van Hilten (Leiden, Netherlands)

  • Exploring the brainstem functions in cervical dystonia

    P. Tocco, M.C. Tozzi, S. Monaco, L. Bertolasi (Verona, Italy)

  • Exploring therapeutic viability of a non-dopaminergic target for Parkinson’s disease

    A. Ashrafi, M. Buttini, P. Garcia, A. del Sol, E. Glaab (Esch-sur-Alzette, Luxembourg)

  • Extended-release carbidopa-levodopa, IPX066: Dosing and efficacy with concomitant medication use in Parkinson’s disease

    S. Gupta, S. Khanna, S. Kell, R. Rubens (Hayward, CA, USA)

  • Extensive bilateral basal ganglia and cerebellar calcification in Fahr’s syndrome after thyroidectomy

    T. Uyar, K. Paksoy, C. Çokluk (Rize, Turkey)

  • Eye movement abnormalities in essential tremor and other neurodegenerative diseases (Parkinson’s disease, spino-cerebellar ataxia, Huntington disease)

    M. Wojcik-Pedziwiatr, M. Rudzinska, K. Zajdel, W. Soltan, J. Slawek, A. Szczudlik (Krakow, Poland)

  • Eye tracking-based measurement of cognitive functions in patients with neurodegenerative diseases

    H. Schmitz-Peiffer, K. Linse, W. Rüger, M. Joos, M. Löhle, A. Storch, A. Hermann (Dresden, Germany)

Jump to:  View All • a b c d [e] f g h i j k l m n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley